GRM7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL481153	1.00	10/20
SCHEMBL346142	0.83	7/20
SCHEMBL346141	0.59	5/20
SCHEMBL346140	0.52	5/20
SCHEMBL297862	0.51	5/20
SCHEMBL299819	0.49	5/20
SCHEMBL173390	0.53	4/20
SCHEMBL173391	0.50	4/20
SCHEMBL173705	0.50	4/20
SCHEMBL254854	0.49	4/20
SCHEMBL298806	0.41	4/20
SCHEMBL173219	0.50	3/20
SCHEMBL56509	0.48	3/20
SCHEMBL255286	0.46	3/20
SCHEMBL304269	0.44	3/20
SCHEMBL304271	0.44	3/20
SCHEMBL252030	0.44	3/20
SCHEMBL252270	0.44	3/20
SCHEMBL416486	0.39	3/20
D-Glutamate (SCHEMBL2201)	1.00	2/20

Clinical trials — most relevant to GRM7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation	PHASE3	COMPLETED
Tryptophan MRI in People With Schizophrenia and Healthy Controls	PHASE2/PHASE3	COMPLETED
Varenicline (Chantix™) for the Treatment of Alcohol Dependence	PHASE2	COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
TRPM8 Activators for Peripheral Neuropathy	PHASE2	ACTIVE_NOT_RECRUITING
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	PHASE1	RECRUITING
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
Diclofenac Dose Response Study	PHASE1	RECRUITING
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain	PHASE1	COMPLETED
A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers	PHASE1	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
Acamprosate: Genes Associated With Response	nan	COMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
Metabotropic Receptors For Glutamate Type 3 In Parkinson's	nan	UNKNOWN
Pulsed Electro Magnetic Fields (PEMF) in Depression	nan	COMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRM7 binder may also engage these)

Protein	Name	Similarity
Q68ED2	—	1.000	Q68ED2 →
Q5RDQ8	—	1.000	Q5RDQ8 →
P35400	—	1.000	P35400 →
GRM8	Metabotropic glutamate receptor 8	0.998	landscape →
P47743	—	0.997	P47743 →
P70579	—	0.996	P70579 →
GRM4	Metabotropic glutamate receptor 4	0.957	landscape →
Q68EF4	—	0.957	Q68EF4 →
P31423	—	0.953	P31423 →
Q1ZZH0	—	0.952	Q1ZZH0 →
GRIN3A	Glutamate receptor ionotropic, NMDA 3A	0.937	landscape →
Q9R1M7	—	0.936	Q9R1M7 →
Q9ULV1	—	0.934	Q9ULV1 →
TRPC7	Short transient receptor potential channel 7	0.932	landscape →
A2AIR5	—	0.931	A2AIR5 →
Q9IA05	—	0.931	Q9IA05 →
Q61088	—	0.930	Q61088 →
Q62956	—	0.927	Q62956 →
Q9WVC5	—	0.927	Q9WVC5 →
Q5ZIN0	—	0.926	Q5ZIN0 →
Q7TMS5	—	0.926	Q7TMS5 →
Q9QZH0	—	0.925	Q9QZH0 →
P51798	—	0.925	P51798 →
O70496	—	0.925	O70496 →
Q5MB13	—	0.924	Q5MB13 →
P98200	—	0.924	P98200 →
P24045	—	0.924	P24045 →
P16068	—	0.923	P16068 →
ERBB4	Receptor tyrosine-protein kinase erbB-4	0.923	landscape →
P20595	—	0.923	P20595 →